Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

GPhC to launch consultation on 2011 fees

The General Pharmaceutical Council (GPhC) is set to launch a consultation on its fees for 2011 next week, C+D understands.

 

The GPhC discussed the proposals on Wednesday and although some changes were being made to the consultation document prior to its release, these did not affect the proposed figures, GPhC chief executive and registrar Duncan Rudkin told C+D.

 

The proposed renewal fee is £262 for pharmacists and £142 for pharmacy technicians.

 

This fee and the professional leadership’s body’s fee of £192 come to a total of £454, so £32 more than the current RPSGB fee of £422.

 

Steve Churton, president of the RPSGB, said he was disappointed that the GPhC had been unable to keep the total costs of regulation and professional leadership to within the current combined fee plus inflation.

 

“It is true that any organisation going through a de-merger is likely to lose some efficiency, but it is not clear why the total regulatory burden has increased so substantially,” he said.

 

But Mr Rudkin said the GPhC had looked at the RPSGB regulation budgets and costs as a way of cross-checking whether their own cost projections were reasonable and sensible.

 

He stressed that making a profit was “not on the agenda at all” for the GPhC.

 

Pharmacists could comment on the proposed fees as part of the consultation process, Mr Rudkin added.

 

For more details of C+D’s interview with Mr Rudkin see C+D May 29.

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD012675

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel